Alzheimer's-Related Psychosis Clinical Trials

Home | Studies | Alzheimer’s Disease (Psychosis)

Explore Alzheimer’s-Related Psychosis Clinical Trials Investigating Potential Novel Treatment Options!

We are conducting a clinical trial for a potential treatment for patients living with Alzheimer’s disease with psychosis condition.

Alzheimer Psychosis disease encompasses delusions, hallucinations, or other distortions of reality, impacting approximately 30% of individuals with the condition. Delusions often entail false beliefs or misconceptions, such as mistaking a loved one for an imposter or suspecting theft of possessions. Hallucinations involve perceiving non-existent stimuli, like seeing or hearing things absent from others. While the precise cause of psychosis in Alzheimer’s remains incompletely understood, it is thought to stem from the intricate brain changes occurring in the disease.

Revive Research Institute is conducting potential treatment for Alzheimer disease to investigate innovative solutions that may help people manage their Alzheimer psychosis.

You may qualify for the clinical trial if you:

Are between the ages of 55 to 95 years old
Have been diagnosed with mild to severe Alzheimer disease with moderate to severe Psychosis (hallucinations and/or delusions)
Have a caregiver who will be able to attend all visits, report on participant’s status, oversee medication and treatment, and participate in some written study assessments.

*Additional criteria may apply

*Take part in this clinical research trial at no cost to you or your private medical insurance. You will be reimbursed financially for your time and travel. In addition, all participants get free study-related treatment from Doctors and Healthcare experts.

*If you are interested in participating in the Alzheimer’s Disease Clinical Trial or would like more information, please fill out the form so we can determine if you qualify for the study and contact you. Note that this is an entirely voluntary decision. If you change your mind about participating in a study, you can leave at any time.

*Who is this information for?

A Family Member

A Friend

My Patient

Please provide YOUR contact information only.

First Name

Last Name

Phone

Confirm Phone

Best time to call?

Morning

Middle of the day

Evening

state

How did you hear about us?

Comments

*User Agreement

By Signing up, I agree to be contacted via calls and SMS.

For more info, please visit Privacy Policy.

Alzheimer's Related Psychosis Clinical Trials

About the Alzheimer Psychosis Research study

Psychosis due to Alzheimer’s is a distressing and challenging aspect of the illness, often present in the later stages. We are conducting Alzheimer’s-related Psychosis Clinical Trials. These clinical trials assess the efficacy and safety of an oral drug in older adults (55-95 years of age) males and females with psychotic symptoms. Participants in this Alzheimer’s Disease Psychosis Clinical Trial will be given a potential treatment as an adjuvant to standard treatment if they have not responded to their current therapy regime.

To ensure study eligibility, all participants must comply with all study procedures. Participants who meet the eligibility criteria for Alzheimer’s-related Psychosis Clinical Trials and are selected to participate will receive a call from our research team and may be called onto the site. We are looking into the safety and efficacy of an oral study drug which may be a potential treatment for patients living with Alzheimer’s disease with psychosis condition.

*There is no cost to you, your private medical insurance, or the public health insurance plan for study procedures. The study drug, related procedures, and visits will be provided at no charge for the study.

Get Started: What to Expect?

If you are suffering from this condition and want to participate in our Alzheimer’s-related Psychosis Clinical Trials conducted in Michigan, please contact us by filling out the form below. these trials will provide potential treatment for patient living with Alzheimer’s disease with psychosis condition. One of our study team representatives will call you to see if you are a fit for this study (pre-screening).

Someone from the research team will ask you to sign an Informed Consent Form (ICF), if you meet the study requirements during the pre-screening process. Once you sign up for the ICF, we will invite you for a screening visit to our clinical site; this will be an initial visit. After that, you will undergo a series of health-related questions and tests to confirm your eligibility as a participant.

Once you receive eligibility confirmation, you will formally be part of the Alzheimer Psychosis clinical trials. You will receive all the information about the research study you might enroll in during the ICF process.

*All study-related care is provided free of cost. Complete physical examination and other study-related assessments will be done by expert psychiatrists and health care experts.

Condition

Alzheimer’s Disease-related Psychosis

Age

55-95 years

Location

Illinois & Michigan

About Alzheimer Psychosis Disease

Patients living with Alzheimer disease with Psychosis condition manifests with a range of distressing symptoms. Hallucinations, where individuals perceive stimuli not actually present, and delusions, involving strongly held false beliefs, commonly occur. These symptoms exacerbate confusion, anxiety, and behavioral changes, posing challenges for both affected individuals and their caregivers.

Causes

The precise origins of psychosis in Alzheimer’s are multifaceted and interconnected. Neurodegenerative processes in the brain, along with chemical imbalances, contribute to the onset of psychotic symptoms.

Risk Factors

Numerous factors heighten the risk of psychosis in Alzheimer’s. Advanced age, particularly in later stages, stands out as a primary risk factor. Genetic predispositions, such as the APOE-e4 gene, amplify susceptibility. A history of psychiatric conditions, including depression, and certain medications can also increase the likelihood of psychosis development.

Frequently Asked Questions (FAQs)

1. What proportion of individuals with Alzheimer's disease experience psychosis?

Approximately 8 million people in the US are affected by Alzheimer’s disease, with about 2.4 million experiencing Alzheimer’s disease-related psychosis, including hallucinations and delusions.

2. How is psychosis identified in Alzheimer's disease?

To diagnose a psychotic disorder, doctors will take a medical and psychiatric history and perform a brief physical exam.

3. What are the treatment options for Alzheimer psychosis?

Atypical antipsychotics are commonly prescribed as initial treatments for patients experiencing psychotic symptoms associated with Alzheimer’s disease. Potential treatment for patient living with Alzheimer’s disease with psychosis condition are also provided through clinical trials.

4. Is there a fee associated with participating in a clinical trial?

Participation in Alzheimer’s disease clinical trials is free of charge for both individuals and their private insurance. If you qualify and choose to participate, you will receive financial compensation for your time and travel expenses. Further details regarding the compensation will be provided upon completion of the screening process and commencement of the informed consent procedure.

5. What are the experiences of individuals living with Alzheimer's disease psychosis?

Living with Alzheimer’s disease wants to navigate through a distorted reality, where hallucinations and delusions blur the boundary between the familiar and the imagined, posing a constant challenge to one’s perception of self and surroundings.

Alzheimer's-related Psychosis Clinical Trials